Intrinsic Value

The intrinsic value of Ginkgo Bioworks Holdings Inc (DNA) under the Base Case is 3.86 USD per share. Compared with the current market price of 8.5 USD, the stock appears Overvalued by 55% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

DNA Intrinsic Value
$3.86
Overvaluation 55%
Intrinsic Value
Price $8.5
Alert me when DNA is below its intrinsic value
Today $3.09 · 63.6% below the current price

DNA is valued in line with its history. A premium of this size has been typical over the past 5 years.

Alternatives to DNA

Fundamental Analysis

What Ginkgo Bioworks Does

Life Sciences Tools & Services Health Care

Ginkgo Bioworks builds and programs cells for other companies. It uses genetics, automation, and lab software to design microbes that can make useful ingredients, chemicals, materials, or help with testing and diagnostics. In simple terms, it is a synthetic biology company that helps turn biology into an engineering process.

Headquarters
United States of America US
Employees
485
IPO date
Apr 19, 2021
Read the full company overview
View Company Overview

Ginkgo Bioworks Holdings has no economic moat

No Moat Narrow Wide

Ginkgo Bioworks Holdings Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.

Read the full moat analysis
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Ownership

Ginkgo Bioworks Holdings insiders are selling within their usual range

Insider trading · Last trade on Oct 19, 2026

Sold $4.5m 5 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Continue DNA Research

Decided on Ginkgo Bioworks Holdings? Get an email when DNA reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one DNA stock?

The intrinsic value for Ginkgo Bioworks Holdings Inc (DNA) under the Base Case is 3.86 USD.

Is DNA stock undervalued or overvalued?

Compared with the current market price of 8.5 USD, the stock appears Overvalued by 55% .

How reliable are our estimates? See how past valuations played out
Back to Top